Sutro Biopharma Announces Updated Data from Phase 1b Study of Luvelta in Combination with Bevacizumab at ESMO 2024 (GlobeNewswire) - Sep 14, 2024 - P1 | N=58 | NCT05200364 | Sponsor: Sutro Biopharma, Inc. | "The expansion phase of the study is ongoing at the recommended phase 2 dose (RP2D) of luvelta (4.3 mg/kg) in combination with bevacizumab (15 mg/kg) with an additional 23 patients enrolled to date; initial data is expected in the first half of 2025...Luvelta plus bevacizumab demonstrated encouraging antitumor activity in 17 RECIST evaluable patients: At the RP2D (4.3 mg/kg), an Objective Response Rate (ORR) of 56% (5/9) was observed; no (0/6) patients had a response at 3.5 mg/kg and 50% (1/2) of patients had a response at 5.2 mg/kg. An ORR of 35% (6/17) was observed in the overall population with a median duration of response of 9.3 months. In patients with ≥25% FRα expression, an ORR of 44% (4/9) was observed; in patients with <25% FRα expression, an ORR of 29% (2/7) was observed. No new safety signals were observed compared with either agent alone..."
P1 data • Gynecologic Cancers • Oncology • Ovarian Cancer • Solid Tumor
|